BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/25/2019 3:13:57 AM | Browse: 866 | Download: 1336
 |
Received |
|
2019-02-06 03:22 |
|
Peer-Review Started |
|
2019-02-06 13:47 |
|
To Make the First Decision |
|
2019-03-14 06:51 |
|
Return for Revision |
|
2019-03-14 07:10 |
|
Revised |
|
2019-03-18 05:49 |
|
Second Decision |
|
2019-03-22 08:25 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2019-03-25 04:40 |
|
Articles in Press |
|
2019-03-25 04:40 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2019-04-16 02:02 |
|
Publish the Manuscript Online |
|
2019-04-25 03:13 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Opinion Review |
| Article Title |
Development of Helicobacter pylori treatment: How do we manage antimicrobial resistance?
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Sho Suzuki, Mitsuru Esaki, Chika Kusano, Hisatomo Ikehara and Takuji Gotoda |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Sho Suzuki, MD, PhD, Doctor, Research Associate, Division of Gastroenterology and Hepatology, Department of Medicine, Nihon University School of Medicine, 1-6 Kanda-Surugadai, Chiyoda-ku, Tokyo 1018309, Japan. suzuki.sho@nihon-u.ac.jp |
| Key Words |
Helicobacter pylori; Antibiotic resistance; Antimicrobial resistance; Dual therapy; Vonoprazan |
| Core Tip |
The increasing antimicrobial resistance of Helicobacter pylori (H. pylori) is an urgent, global issue. Although current H. pylori treatment regimens provide acceptable eradication rates, these regimens could also be improved to optimize antibiotic usage and prevent antimicrobial resistance because these regimens use multiple antibiotic agents and have a long treatment duration. Dual therapy consisting of vonoprazan and amoxicillin may be an alternative treatment regimen for H. pylori eradication in an era of growing antimicrobial resistance and may provide sufficient H. pylori eradication rates and may help prevent future antimicrobial resistance of H. pylori. |
| Publish Date |
2019-04-25 03:13 |
| Citation |
Suzuki S, Esaki M, Kusano C, Ikehara H, Gotoda T. Development of Helicobacter pylori treatment: How do we manage antimicrobial resistance? World J Gastroenterol 2019; 25(16): 1907-1912 |
| URL |
https://www.wjgnet.com/1007-9327/full/v25/i16/1907.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v25.i16.1907 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
